tiprankstipranks
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market
SABS
SAB Biotherapeutics
RESEARCH TOOLSreports

SAB Biotherapeutics (SABS) Financial Statements

Compare
317 Followers

SAB Biotherapeutics Financial Overview

SAB Biotherapeutics's market cap is currently $196.16M. The company's EPS TTM is $-0.21; its P/E ratio is 5.44; SAB Biotherapeutics is scheduled to report earnings on March 26, 2026, and the estimated EPS forecast is $-0.21. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Mar 25Dec 23Mar 23Dec 21
Income Statement
Total Revenue$ 0.00$ 1.32M$ 2.24M$ 23.90M$ 60.88M
Gross Profit$ -3.08M$ -3.47M$ -1.51M$ 20.61M$ 59.22M
Operating Income$ -48.95M$ -42.91M$ -38.08M$ -28.92M$ -13.39M
EBITDA$ 16.60M$ -28.99M$ -38.13M$ -15.12M$ -15.20M
Net Income$ 13.27M$ -34.11M$ -42.19M$ -18.74M$ -17.14M
Balance Sheet
Cash & Short-Term Investments$ 96.59M$ 20.76M$ 56.57M$ 15.05M$ 33.21M
Total Assets$ 172.81M$ 44.20M$ 83.94M$ 50.90M$ 81.14M
Total Debt$ 5.95M$ 4.67M$ 5.91M$ 5.93M$ 8.52M
Net Debt$ -4.55M$ -4.23M$ -50.66M$ -9.12M$ -24.69M
Total Liabilities$ 21.32M$ 18.23M$ 26.64M$ 19.85M$ 42.59M
Stockholders' Equity$ 151.49M$ 25.97M$ 57.30M$ 31.06M$ 38.55M
Cash Flow
Free Cash Flow$ -45.71M$ -34.63M$ -25.32M$ -25.63M$ -8.96M
Operating Cash Flow$ -44.78M$ -34.29M$ -25.12M$ -23.46M$ 1.99M
Investing Cash Flow$ -121.71M$ -11.96M$ -152.70K$ -2.09M$ -10.94M
Financing Cash Flow$ 168.30M$ -1.17M$ 66.77M$ 1.05M$ 35.89M
Currency in USD

SAB Biotherapeutics Earnings and Revenue History

Income Statement >

SAB Biotherapeutics Debt to Assets

Balance Sheet >

SAB Biotherapeutics Cash Flow

Cash Flow >

SAB Biotherapeutics Forecast EPS vs Actual EPS

Earnings >